Heidelberg Pharma AG (HPHA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Merck KGaA

Dermapharm Holding SE

PharmaSGP Holding SE

Bayer AG

Formycon AG

Evotec SE

PAION AG

Heidelberg Pharma AG

Haemato AG

APONTIS PHARMA AG

Biofrontera AG

Why is Heidelberg Pharma AG ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -28.56% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -23.70

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 14.61%, its profits have fallen by -39.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Heidelberg Pharma AG for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Heidelberg Pharma AG

20.68%

0.13

56.55%

Germany DAX (TR)

12.87%

1.26

19.31%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-18.82%

EBIT Growth (5y)

-28.56%

EBIT to Interest (avg)

-23.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.24

Sales to Capital Employed (avg)

0.80

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

13.24

EV to EBIT

-4.83

EV to EBITDA

-4.97

EV to Capital Employed

6.32

EV to Sales

50.41

PEG Ratio

Dividend Yield

ROCE (Latest)

-130.70%

ROE (Latest)

-248.59%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is not working for Heidelberg Pharma AG

Net Sales - Quarterly

At EUR 1 MM has Fallen at -38.94 %

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (EUR MM)

Inventory Turnover Ratio- Half Yearly

Lowest at 0.79 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Operating Cash Flow - Annually

Lowest at EUR -33.67 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (EUR MM)

Net Sales - Quarterly

Lowest at EUR 1 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (EUR MM)

Cash and Cash Equivalents - Half Yearly

Lowest at EUR 32.65 MM

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents (EUR MM)